E. Loret

发表

Didehydro-Cortistatin A Inhibits HIV-1 by Specifically Binding to the Unstructured Basic Region of Tat

Ian Mitchelle S. de Vera, J. Nowak, D. Kojetin, 2019, mBio.

An anti-insect toxin purified from the scorpion Androctonus australis Hector also acts on the alpha- and beta-sites of the mammalian sodium channel: sequence and circular dichroism study.

C. Granier, H. Rochat, P. Mansuelle, 1991, Biochemistry.

Identification of Structural Elements of a Scorpion α-Neurotoxin Important for Receptor Site Recognition*

D. Arad, O. Froy, D. Gordon, 1997, The Journal of Biological Chemistry.

Sodium channel modifiers from scorpion venom: structure-activity relationship, mode of action and application.

V. Tugarinov, J. Anglister, M. Adams, 1998, Toxicon : official journal of the International Society on Toxinology.

The Putative Bioactive Surface of Insect-selective Scorpion Excitatory Neurotoxins*

Oren Froy, Boaz Shaanan, O. Froy, 1999, The Journal of Biological Chemistry.

Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.

Shiu-Lok Hu, M. Robert-Guroff, D. Forthal, 2014, Vaccine.

Ulva lactuca, A Source of Troubles and Potential Riches

H. Domínguez, E. Loret, 2019, Marine drugs.

Correlation of antiviral activity with beta-turn types for V3 synthetic multibranched peptides from HIV-1 gp120.

H. Rochat, K. Mabrouk, E. Loret, 1995, Biochemistry.

On the binding of two scorpion toxins to the central nervous system of the cockroach Periplaneta americana

H. Rochat, C. Diniz, E. Loret, 1989 .

Seaweed and Sea Anemones Proteins as a Source of New Pharmaceutical Active Principles

H. Domínguez, N. Flórez-Fernández, M. Torres, 2020 .

A Low Molecular Weight Protein from the Sea Anemone Anemonia viridis with an Anti-Angiogenic Activity

R. Lebrun, P. Mansuelle, E. Loret, 2018, Marine drugs.

Positively charged amino acid residues located similarly in sea anemone and scorpion toxins.

H. Rochat, P. Mansuelle, E. Loret, 1994, The Journal of biological chemistry.

Structure Function Relationships of KTS Disintegrins and Design of Antiangiogenic Drugs

J. Sabatier, E. Loret, M. Ayeb, 2010 .

Tat-specific binding IgG and disease progression in HIV type 1-infected Ugandans.

P. Kaleebu, L. Shafer, E. Loret, 2008, AIDS research and human retroviruses.

Two purified and characterized phospholipases A2 from Cerastes cerastes venom, that inhibit cancerous cell adhesion and migration.

S. Bezzine, N. Srairi-Abid, M. El Ayeb, 2009, Toxicon : official journal of the International Society on Toxinology.

Tat mutations in an African cohort that do not prevent transactivation but change its immunogenic properties.

P. Kaleebu, S. Opi, E. Loret, 2007, Vaccine.

Specificity and effect on apoptosis of Tat antibodies from vaccinated and SHIV-infected rhesus macaques and HIV-infected individuals.

A. Romieu, B. Roques, J. Zagury, 2003, Vaccine.

Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine

J. Salles, S. Opi, Sophie Lancelot, 2006, Retrovirology.

Scorpion Toxins Affecting Insects

C. Granier, H. Rochat, E. Loret, 1992 .

Discovery of a Tat HIV-1 Inhibitor through Computer-Aided Drug Design

C. Pannecouque, J. Sturgis, E. Clercq, 2003 .

Cutting edge: HIV-1 Tat protein differentially modulates the B cell response of naive, memory, and germinal center B cells.

E. Lefèvre, Y. Richard, P. Galanaud, 1999, Journal of immunology.

Cellsof Naive, Memory, and Germinal Center B Differentially Modulates the B Cell Response Cutting Edge: HIV-1 Tat Protein

E. Lefèvre, Y. Richard, P. Galanaud, 1999 .

Homonuclear (1)H-NMR assignment and structural characterization of human immunodeficiency virus type 1 Tat Mal protein.

S. Opi, E. Loret, G. Campbell, 2001, Biopolymers.

Mechanism of Calcite Crystal Growth Inhibition by the N-terminal Undecapeptide of Lithostathine*

V. Gerbaud, D. Pignol, J. Fontecilla-Camps, 2000, The Journal of Biological Chemistry.

Circular dichroism and molecular modeling yield a structure for the complex of human immunodeficiency virus type 1 trans-activation response RNA and the binding region of Tat, the trans-acting transcriptional activator.

P. S. Ho, P. Georgel, E. Loret, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Acetylation of Tat defines a cyclinT1-independent step in HIV transactivation.

V. Kiermer, E. Verdin, A. Dorr, 2003, Molecular cell.

Differential acetylation of Tat coordinates its interaction with the co‐activators cyclin T1 and PCAF

K. Jeang, Y. Nakatani, M. Benkirane, 2002, The EMBO journal.

Evolution of maurotoxin conformation and blocking efficacy towards Shaker B channels during the course of folding and oxidation in vitro.

E. Carlier, H. Rochat, M. De Waard, 2002, The Biochemical journal.

Phosphatidylinositol‐(4,5)‐bisphosphate enables efficient secretion of HIV‐1 Tat by infected T‐cells

S. Arold, F. Rayne, S. Debaisieux, 2010, The EMBO journal.

Large fragments of nef-protein and gp110 envelope glycoprotein from HIV-1. Synthesis, CD analysis and immunoreactivity.

L. Montagnier, C. Granier, H. Rochat, 2009, International journal of peptide and protein research.

Antiretroviral therapy does not block the secretion of the human immunodeficiency virus tat protein.

S. Spector, P. Brouqui, A. Stein, 2012, Infectious disorders drug targets.

The C Terminus of HIV-1 Tat Modulates the Extent of CD178-mediated Apoptosis of T Cells*

Eddy Pasquier, E. Pasquier, S. Spector, 2005, Journal of Biological Chemistry.

The Glutamine-rich Region of the HIV-1 Tat Protein Is Involved in T-cell Apoptosis*

Eddy Pasquier, Diane Braguer, Pontiano Kaleebu, 2004, Journal of Biological Chemistry.

HIV-1 Clade B Tat, but Not Clade C Tat, Increases X4 HIV-1 Entry into Resting but Not Activated CD4+ T Cells*

S. Spector, E. Loret, G. Campbell, 2009, The Journal of Biological Chemistry.

Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial

O. Blin, E. Jouve, B. Dussol, 2016, Retrovirology.

Identification of a Highly Conserved Surface on Tat Variants*

C. Devaux, S. Mediouni, E. Loret, 2013, The Journal of Biological Chemistry.

A Monoclonal Antibody Directed against a Conformational Epitope of the HIV-1 Trans-activator (Tat) Protein Neutralizes Cross-clade

M. Pierres, S. Mediouni, E. Loret, 2012, The Journal of Biological Chemistry.

Tat HIV-1 Primary and Tertiary Structures Critical to Immune Response Against Non-homologous Variants*

E. Bouveret, A. Walburger, S. Opi, 2002, The Journal of Biological Chemistry.

HIV-1 infected patients have antibodies recognizing folded Tat.

S. Mediouni, E. Loret, I. Ravaux, 2011, Infectious Diseases - Drug Targets.

What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?

E. Loret, G. Campbell, 2009, Retrovirology.

Homonuclear 1H NMR and circular dichroism study of the HIV-1 Tat Eli variant

E. Loret, G. Campbell, H. Halimi, 2008, Retrovirology.

1H-13C nuclear magnetic resonance assignment and structural characterization of HIV-1 Tat protein.

C. Pannecouque, D. Olive, C. Bailly, 2000, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

Conformational Heterogeneity in Two Regions of TAT Results in Structural Variations of This Protein as a Function of HIV-1 Isolates*

E. Loret, C. Gregoire, 1996, The Journal of Biological Chemistry.

HIV-1 Tat protein enhances Microtubule polymerization

M. Carré, D. Braguer, P. Barbier, 2005, Retrovirology.

Differential induction of rat neuronal excitotoxic cell death by human immunodeficiency virus type 1 clade B and C tat proteins.

S. Spector, E. Loret, G. Campbell, 2011, AIDS research and human retroviruses.

Specific Binding of Dehydroepiandrosterone to the N Terminus of the Microtubule-associated Protein MAP2*

D. Lafitte, C. Briand, E. Loret, 2003, Journal of Biological Chemistry.

Human Immunodeficiency Virus Type 1 Subtype C Tat Fails To Induce Intracellular Calcium Flux and Induces Reduced Tumor Necrosis Factor Production from Monocytes

S. Spector, K. Singh, E. Loret, 2007, Journal of Virology.

Affinity for the cognate monoclonal antibody of synthetic peptides derived from selection by phage display. Role of sequences flanking thebinding motif.

D. Laune, C. Granier, B. Pau, 2000, European journal of biochemistry.

Erratum to: Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial

O. Blin, E. Jouve, B. Dussol, 2016, Retrovirology.

Full Peptide Synthesis, Purification, and Characterization of Six Tat Variants

D. Olive, C. Bailly, E. Meurs, 1999, The Journal of Biological Chemistry.

Scorpion neurotoxins: structure/function relationships and application in agriculture†

Oren Froy, Boaz Shaanan, J. Anglister, 2000 .

Full-length HIV-1 Tat protein necessary for a vaccine.

P. Kaleebu, K. Jeang, S. Opi, 2004, Vaccine.

APETx1, a new toxin from the sea anemone Anthopleura elegantissima, blocks voltage-gated human ether-a-go-go-related gene potassium channels.

M. Lazdunski, S. Diochot, T. Bruhn, 2003, Molecular pharmacology.

Conformational analysis of the Campylobacter jejuni porin

J. Pagés, J. Bolla, E. Loret, 1995, Journal of bacteriology.

Neurotoxins active on insects: amino acid sequences, chemical modifications, and secondary structure estimation by circular dichroism of toxins from the scorpion Androctonus australis Hector.

C. Granier, H. Rochat, P. Mansuelle, 1990, Biochemistry.

A possible improvement for structure-based drug design illustrated by the discovery of a Tat HIV-1 inhibitor.

C. Bailly, S. Opi, A. Aubertin, 2004, Bioorganic & medicinal chemistry letters.

In Vitro Characterization of Peptidoglycan-Associated Lipoprotein (PAL)–Peptidoglycan and PAL–TolB Interactions

E. Bouveret, C. Lazdunski, H. Bénédetti, 1999, Journal of bacteriology.

HIV extracellular Tat: myth or reality?

E. Loret, 2015, Current HIV research.

Circular dichroism and molecular modeling of the E. coli TolA periplasmic domains.

S. Sasso, C. Lazdunski, E. Loret, 1999, Biospectroscopy.

Conformational Analysis of theCampylobacter jejuniPorin

J. Bolla, E. Loret, M. Zalewski, 1995 .

Activating region of HIV-1 Tat protein: vacuum UV circular dichroism and energy minimization.

E. Vivés, P. S. Ho, H. Rochat, 1991, Biochemistry.

No tRNA3 Lys Unwinding in a Complex with HIV NCp7*

D. Gautheret, E. Loret, C. Gregoire, 1997, The Journal of Biological Chemistry.

HIV-1 Tat protein enhances Microtubule polymerization

M. Carré, D. Braguer, P. Barbier, 2015 .

Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine

J. Salles, S. Opi, Sophie Lancelot, 2006, Retrovirology.

Conformational flexibility of a scorpion toxin active on mammals and insects: A circular dichroism study

C. Granier, A. Roussel, H. Rochat, 1990, Proteins.

HIV-1 Tat protein enhances Microtubule polymerization

M. Carré, D. Braguer, P. Barbier, 2005, Retrovirology.

Conformational analysis of t immunogenic peptides by circular dichroism spectroscopy

J. Claverie, C. Abergel, E. Loret, 1989, European journal of immunology.